Gilead's Tecartus shows long-term overall survival in type of lymphoma
Dr_Microbe         

Gilead Sciences' (NASDAQ:GILD) Kite unit said that three-year, follow-up results indicated that itsÂ CAR T-cell therapy TecartusÂ demonstrated durable overall survival (OS) in patients withÂ B-cell acute lymphoblastic leukemia.
Data showed that Tecartus (brexucabtagene autoleucel) treatment lead to median OS of 26 months. Median OS wasÂ 38.9 months for patients with complete remission or complete remission with incomplete hematologic recovery.
Study participants were heavily pre-treated. A median had two prior therapies, while 47% had received at least three.
Earlier in February, Gilead (GILD) raised its dividend.